Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

Blood

Volumn 132, Issue 6, 2018, Pages 662-666

  Nellan, Anandani ^a   Lester McCully, Cynthia M ^b   Garcia, Rafael Cruz ^b   Jayaprakash, Nalini ^b   Widemann, Brigitte C ^b   Lee, Daniel W ^c   Warren, Katherine E ^b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; ELIMINATION RATE CONSTANT; LETTER; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RHESUS MONKEY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; BLOOD BRAIN BARRIER; COMPARATIVE STUDY; HALF LIFE TIME; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; HALF-LIFE; INFUSIONS, INTRAVENTRICULAR; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE;

EID: 85051407904     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-05-846428     Document Type: Letter

References (19)

1. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
2. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-528.
3. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
4. Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016:567-572.
5. Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016;9(1):70.
6. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]. Blood. 2014;124(2):188-195.
7. Gust J, Hay KA, Hanafi L-A, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404-1419.
8. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122.
9. Mackall CL, Miklos DB. CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity. Cancer Discov. 2017;7(12): 1371-1373.
10. Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018;8(6):750-763.
11. Blecharz K, Wagner J, Fries A, et al. Interleukin 6-mediated endothelial barrier disturbances can be attenuated by blockade of the IL6 receptor expressed in brain microvascular endothelial cells [published online ahead of print 10 February 2018]. Transl Stroke Res. doi:10.1007/s12975-018-0614-2.
12. Council NR. Guide for the care and use of laboratory animals, 8th ed. Washington, D.C.: National Academies Press; 2010.
13. Lester McCully CM, Bacher J, MacAllister RP, et al. Development of a cerebrospinal fluid lateral reservoir model in rhesus monkeys (Macaca mulatta). Comp Med. 2015;65(1):77-82.
14. MacAllister RP, Lester McCully CM, Bacher J, et al. Minimally invasive lumbar port system for the collection of cerebrospinal fluid from rhesus macaques (Macaca mulatta). Comp Med. 2016;66(4):349-352.
15. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4): 219-244.
16. Alten R. Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2011;3(3):133-149.
17. Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8: 349-364.
18. Kneepkens EL, van den Oever I, Plasencia CH, et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol. 2017;46(2):87-94.
19. League-Pascual JC, Lester-McCully CM, Shandilya S, et al. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. J Neurooncol. 2017;132(3):401-407.